Opinion

Video

ADT Treatment Considerations and Unmet Needs in Prostate Cancer

Author(s):

Lawrence Karsh, MD, FACS,Stephen J. Freedland, MD

Experts on prostate cancer discuss current unmet needs in the therapeutic landscape and outline treatment considerations for patients receiving androgen deprivation therapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • What are the current unmet needs in prostate cancer treatment?
        • Please provide your perspectives on the use of ADT in patients with prostate cancer and mitigating any potential cardiometabolic risk factors in the future.
      Related Videos
      Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
      Study findings highlight gender gaps in oncology authorship and citation
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      1 expert in this video
      Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
      1 expert in this video
      Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tips for PCPs on evaluating prostate cancer risk
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tailoring prostate cancer care for older adults
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: New strategies emerge for metastatic prostate cancer
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
      Related Content
      Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
      May 30th 2025

      PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology

      Benjamin P. Saylor
      The addition of Ra223 to enzalutamide was associated with a 31% reduction in the risk of progression or death compared with enzalutamide alone.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      ORIC-944 shows promise in combination with AR inhibitors in mCRPC
      May 30th 2025

      ORIC-944 shows promise in combination with AR inhibitors in mCRPC

      Hannah Clarke
      Overall, 59% of patients achieved at least a 50% decline in PSA level.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Combination therapy linked to longer OS vs ADT in veterans with mHSPC
      May 27th 2025

      Combination therapy linked to longer OS vs ADT in veterans with mHSPC

      Hannah Clarke
      However, the data did not show any benefit of a docetaxel doublet vs an ARPI doublet.
      FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
      May 21st 2025

      FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

      Hannah Clarke
      The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
      © 2025 MJH Life Sciences

      All rights reserved.